Peng Wang
Associate professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Year:
2026
Year:
2026
Aims PAX8 immunohistochemistry (IHC) is often used to distinguish urothelial carcinomas (UCs) from tumours of renal and Mullerian origin. However, some UCs have been shown to be PAX8‐positive. This study investigates the frequency of PAX8‐positive conventional UCs of the urinary bladder without subtype morphology and/or divergent differentiation and their molecular profiles. Methods One hundred and one consecutive transurethral resections of the urinary bladder from 2019 to 2022 with a diagnosis of conventional urothelial carcinoma (UC) without subtype morphology and/or divergent differentiation were retrospectively reviewed. Representative sections were selected for whole‐slide PAX8 IHC (10336‐1‐AP; polyclonal). Next‐generation sequencing (NGS) was performed on all PAX8‐positive cases and on a subset of PAX8‐negative cases. Results PAX8 IHC was positive in 10% (10/101) of cases. Twenty cases underwent NGS, including all 10 PAX8‐positive UCs. All PAX8‐positive UCs had TERT promoter mutations. TSC1 alterations, NOTCH1 loss and WT1 loss were more frequent in the PAX8‐positive cases compared with the PAX8‐negative cases. RB1 loss was not seen in the PAX8‐positive UCs, while it was present in 40% of the PAX8‐negative UCs. Conclusions A subset of conventional UCs of the urinary bladder without subtype morphology and/or divergent differentiation are PAX8‐positive and have frequent alterations in TERT promoter, TSC1 , NOTCH1 , and WT1 , with an absence of RB1 loss. PAX8 positivity should be interpreted with caution if UC is in the differential, and NGS could be helpful in diagnostic workups as this study shows PAX8‐positive UCs may have a distinct molecular profile.
Year:
2026
Year:
2026
PURPOSE A 70-gene liquid biopsy (LB) panel (LBP-70) was implemented at our institution to identify genetic alterations in the plasma of patients with solid tumors. We report the clinical utility of LBP-70 in a retrospective study of 1,243 consecutively tested patients. MATERIALS AND METHODS Electronic medical records were reviewed for relevant clinicopathologic and radiologic information and preanalytical variables, including circulating cell-free DNA yield. The clinical utility of the LBP-70 assay was evaluated on the basis of its ability to identify major tumor drivers and/or targetable alterations and the concordance of the LBP-70 results with tissue genotyping and radiologic findings. RESULTS Positive LB findings were reported in 75% of patients, ranging from 67% to 85% among various tumor types and 60% to 77% in different tumor stages within an average of seven workdays. The mutant allele frequency (AF) ranged from 0.1% to 90%, and 50% of the variants were detected at AF <2%. Overall, LBP-70 provided clinically informative findings in 87% of the patients. In patients with non–small cell lung cancer (NSCLC) and colorectal cancer without tissue specimens, LBP-70 identified informative findings in 74% of patients, including EGFR exon 18-21 mutations in 22% of patients with NSCLC and RAS and/or BRAF V600E mutations in 44% of patients with colorectal cancer. LBP-70 results showed 62% concordance with tissue genotyping and 79% concordance with radiologic findings. CONCLUSION The results of this study demonstrated the clinical utility of LBP-70 in identifying clinically informative findings. LBP-70 is an alternative to tissue-based tumor genotyping and provides a more rapid method for detecting actionable genetic alterations.
Year:
2025
Year:
2024
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort. Supplemental Table 2. List of 80 genes with RNA sequencing coverage. Supplemental Table 3. Demographics of 400 adult ALL cases. Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients. Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients. Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients. Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort. Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients. Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments. Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment. Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.
Year:
2024
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort. Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL. Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations. Supplemental Figure 4. Germline testing in the adult ALL cohort. Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL. Supplemental Figure 6. Overall survival in adults with B-ALL. Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy. Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM). Supplemental Figure 9. Expression levels of lineage-specific surface markers. Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM. Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1. Supplemental Figure 12. Clonal dynamics of ALL with MyM. Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22. Supplemental Figure 14. Clonal evolution of B-ALL2. Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy. Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses. Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab. Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab. Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.
Year:
2024
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort. Supplemental Table 2. List of 80 genes with RNA sequencing coverage. Supplemental Table 3. Demographics of 400 adult ALL cases. Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients. Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients. Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients. Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort. Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients. Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments. Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment. Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.
Year:
2024
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort. Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL. Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations. Supplemental Figure 4. Germline testing in the adult ALL cohort. Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL. Supplemental Figure 6. Overall survival in adults with B-ALL. Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy. Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM). Supplemental Figure 9. Expression levels of lineage-specific surface markers. Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM. Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1. Supplemental Figure 12. Clonal dynamics of ALL with MyM. Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22. Supplemental Figure 14. Clonal evolution of B-ALL2. Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy. Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses. Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab. Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab. Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.
Year:
2024
Year:
2024
Year:
2024
Collaborators (22)
Richard Yang
Assistant Professor, Molecular Genetic Pathology
The University of Texas MD Anderson Cancer Center
Marlise Luskin
Dana-Farber Cancer Institute
Girish Venkataraman
Asst Professor
University of Chicago Pritzker School of Medicine
Sandeep Gurbuxani
Professor
University of Chicago
Rosa Lapalombella
Ohio State University
Anand Ashwin Patel
Assistant Professor of Medicine
-
Adam Sperling
Assistant Professor
Stanford University
Benjamin Ebert
Dana-Farber Cancer Institute
Sinchita Roy‐Chowdhuri
Professor
The University of Texas MD Anderson Cancer Center
Jennifer Bennett
Associate Professor
University of Chicago Medicine
Lachelle Dawn Weeks
Dana-Farber Cancer Institute
Daniel Arber
Professor and Chair
University of Chicago
Ulrich Steidl
Albert Einstein College of Medicine
Lucy A. Godley
Northwestern Medicine
Wendy Stock
Professor of Medicine
University of Chicago
John Greally
Director, New York Center for Rare Diseases (NYCRD)
Albert Einstein College of Medicine
Richard Larson
Professor
University of Chicago
Fatima Zahra Jelloul
The University of Texas MD Anderson Cancer Center
Angela Lager
Assistant Professor
University of Chicago
Chi Young Ok
The University of Texas MD Anderson Cancer Center
Tatjana Antic
University of Chicago
Jung Woo Kwon
Assistant Professor
University of Chicago
Make your next move.
Prepare your application
Review drafts before you send them.